Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase ®
Cephalalgia · 2024-08 · 44 (8)
DOI: 10.1177/03331024241267316 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, online erschienen am 10.08.2024. Verfasst von Sylvie Favrelière und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de Pharmacologie Clinique - Centre Régional de Pharmacovigilance de Poitiers, CHU Poitiers, Poitiers, France. Hauptthemen laut MEDLINE: Pharmacovigilance. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Data on drug-induced reversible cerebral vasoconstriction syndrome (RCVS) are scarce. We aimed to describe RCVS characteristics with drugs previously identified as associated with RCVS and investigate potential signals related to other drugs.
Methods
VigiBase ® was queried for all reports of RCVS until 31 May 2023. A descriptive study was performed on reports concerning drug classes known to precipitate RCVS. To identify new drugs, a disproportionality analysis was conducted.
Results
In total, 560 reports were included. RCVS occurred in patients aged between 45–64 years (40%) and 18–44 years (35%), mainly in females (72.5%). Drugs were antidepressants (38.4%), triptans (6.4%), nasal decongestants (3.7%) and immunosupressants (8.7%). In 50 cases, antidepressants were in association with drugs known to precipitate RCVS. The median time to onset was 195 days for antidepressants and much shorter (1–10 days) for triptans, nasal decongestants and immunosuppressants. The outcome was favorable in 87% of cases, and fatal in 4.4%. We found a disproportionality signal with 14 drugs: glucocorticoids, bupropion, varenicline, mycophenolic acid, aripiprazole, trazodone, monoclonal antibodies (erenumab, ustekinumab and tocilizumab), leuprorelin and anastrozole.
Conclusions
The present study confirms the role of vasoconstrictors in the onset of RCVS, particularly when used in combination and found potential signals, which may help clinicians envisage an iatrogenic etiology of RCVS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de Pharmacologie Clinique - Centre Régional de Pharmacovigilance de Poitiers, CHU Poitiers, Poitiers, France.
- Centre Régional de Pharmacovigilance de Nantes, CHU Nantes, Nantes, France.
- Service de Neurologie CHU Poitiers, Poitiers, France.
ORCID-Profile: Sylvie Favrelière
Zitieren
APA
Favrelière, S., Mahé, J., Veyrac, G., Neau, J. P., Lafay-Chebassier, C., & Pérault-Pochat, M. C. (2024). Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase ®. Cephalalgia, 44(8). https://doi.org/10.1177/03331024241267316
Vancouver
Favrelière S, Mahé J, Veyrac G, Neau JP, Lafay-Chebassier C, Pérault-Pochat MC. Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase ®. Cephalalgia. 2024;44(8). doi:10.1177/03331024241267316
BibTeX
@article{Favrelire2024,
author = {Favrelière, Sylvie and Mahé, Julien and Veyrac, Gwenaelle and Neau, Jean Philippe and Lafay-Chebassier, Claire and Pérault-Pochat, Marie Christine},
title = {Drugs associated with reversible cerebral vasoconstriction syndrome: A pharmacovigilance study in vigiBase ®},
journal = {Cephalalgia},
year = {2024},
volume = {44},
number = {8},
doi = {10.1177/03331024241267316}
}
EUVIMED